Top

Clinical Pharmacokinetics

Published in:

Open Access 01-06-2019 | Original Research Article

Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis

Authors: Amit Khatri, Ling Cheng, Anne Camez, Stanislav Ignatenko, Yinuo Pang, Ahmed A. Othman

Published in: Clinical Pharmacokinetics | Issue 6/2019

Abstract

Objective

The objective of this study was to characterize the effects of risankizumab on the in vivo activity of cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A in psoriasis patients using a cocktail approach.

Methods

Patients with moderate to severe chronic plaque psoriasis (n = 21) received single oral doses of sensitive probe substrates for CYP1A2 (caffeine 100 mg), CYP2C9 (warfarin 10 mg), CYP2C19 (omeprazole 20 mg), CYP2D6 (metoprolol 50 mg), and CYP3A (midazolam 2 mg) on day 1, followed by 12 weeks of subcutaneous risankizumab treatment of 150 mg once every 4 weeks from day 8 to day 92, and again the same cocktail of substrates on day 98. Serial blood samples were collected for determination of the CYP probe drugs and metabolites with and without risankizumab. Trough samples were collected for risankizumab.

Results

The 90% confidence intervals (CIs) for the area under the plasma concentration–time curve (AUC) from time zero to infinity (AUC_∞) ratios for the CYP probe substrates administered with risankizumab versus without risankizumab were within the default 0.8–1.25 equivalence bounds. Similar results were observed for maximum plasma concentration (C_max), except for omeprazole, for which the lower bound of the 90% CI for C_max (0.73) extended slightly below the default equivalence limit. No differences were observed in metabolite-to-parent drug C_max or AUC ratios with risankizumab versus without risankizumab. Risankizumab trough plasma concentrations significantly exceeded those of the phase III regimen of risankizumab in psoriasis (150 mg subcutaneously at weeks 0 and 4 and every 12 weeks thereafter).

Conclusions

Risankizumab did not affect the in vivo activity of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A enzymes in patients with moderate or severe plaque psoriasis and therefore has no potential for drug interactions through these enzymes.

Clinical trial registration

ClinicalTrials.gov Identifier: NCT02772601.

Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, et al. Selective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs. 2015;7(4):778–91.CrossRefPubMedPubMedCentral

Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585–600.CrossRefPubMedPubMedCentral

Campa M, Mansouri B, Warren R, Menter A. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther (Heidelb). 2016;6(1):1–12.CrossRefPubMed

Krueger JG, Ferris LK, Menter A, Wagner F, White A, Visvanathan S, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116–124.e7.CrossRefPubMed

Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551–60.CrossRefPubMed

Mease PJ, Kellner H, Morita A, Kivitz AJ, Papp KA, Aslanyan S, et al. Efficacy and safety results from a phase 2 trial of risankizumab, a selective IL-23 p19 Inhibitor, in patients with active psoriatic arthritis [abstract]. Arthritis Rheum. 2017;69 (suppl 10). http://acrabstracts.org/abstract/efficacy-and-safety-results-from-a-phase-2-trial-of-risankizumab-a-selective-il-23p19-inhibitor-in-patients-with-active-psoriatic-arthritis/. Accessed 6 Dec 2018.

Feagan BG, Sandborn WJ, D’Haens G, Panes J, Kaser A, Ferrante M, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699–709.CrossRefPubMed

AbbVie. Risankizumab meets all co-primary and ranked secondary endpoints, achieving significantly greater efficacy versus standard biologic therapies in three pivotal phase 3 psoriasis studies [press release]. 2017. https://news.abbvie.com/news/risankizumab-meets-all-co-primary-and-ranked-secondary-endpoints-achieving-significantly-greater-efficacy-versus-standard-biologic-therapies-in-three-pivotal-phase-3-psoriasis-studies.htm. Accessed 9 Feb 2018.

AbbVie. Risankizumab meets all primary endpoints reporting positive results in fourth pivotal phase 3 psoriasis study [press release]. 2017. https://news.abbvie.com/news/risankizumab-meets-all-primary-endpoints-reporting-positive-results-in-fourth-pivotal-phase-3-psoriasis-study.htm. Accessed 9 Feb 2018.

10.

AbbVie, A study to assess the efficacy and safety of risankizumab in subjects with moderately to severely active Crohn’s disease who failed prior biologic treatment [ClinicalTrials.gov identifier NCT03104413]. 2018. US National Institutes of Health, ClinicalTrials.gov. https://www.clinicaltrials.gov. Accessed 11 Dec 2018.

11.

AbbVie, A study of the efficacy and safety of risankizumab in subjects with moderately to severely active Crohn’s disease [ClinicalTrials.gov identifier NCT03105128]. 2017. US National Institutes of Health, ClinicalTrials.gov. https://www.clinicaltrials.gov. Accessed 11 Dec 2018.

12.

AbbVie, A multicenter, randomized, double-blind, placebo controlled induction study to evaluate the efficacy and safety of risankizumab in subjects with moderately to severely active ulcerative colitis who have failed prior biologic therapy [ClinicalTrials.gov identifier NCT03398148]. 2018. US National Institutes of Health, ClinicalTrials.gov. https://www.clinicaltrials.gov. Accessed 11 Dec 2018.

13.

Suleiman AA, Khatri A, Minocha M, Othman AA. Population pharmacokinetics of the interleukin-23 inhibitor risankizumab in subjects with psoriasis and Crohn’s disease: analyses of phase I and II trials. Clin Pharmacokinet. 2018. https://doi.org/10.1007/s40262-018-0704-z (Epub 20 Aug 2018).CrossRefPubMedCentral

14.

Cross RK, Wilson KT, Binion DG. Polypharmacy and Crohn’s disease. Aliment Pharmacol Ther. 2005;21(10):1211–6.CrossRefPubMed

15.

Viktil KK, Enstad M, Kutschera J, Smedstad LM, Schjott J. Polypharmacy among patients admitted to hospital with rheumatic diseases. Pharm World Sci. 2001;23(4):153–8.CrossRefPubMed

16.

Gerdes S, Zahl VA, Knopf H, Weichenthal M, Mrowietz U. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol. 2008;159(5):1116–23.CrossRefPubMed

17.

Lee JI, Zhang L, Men AY, Kenna LA, Huang SM. CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet. 2010;49(5):295–310.CrossRefPubMed

18.

Mayo PR, Skeith K, Russell AS, Jamali F. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br J Clin Pharmacol. 2000;50(6):605–13.CrossRefPubMedPubMedCentral

19.

Dumais G, Iovu M, du Souich P. Inflammatory reactions and drug response: importance of cytochrome P450 and membrane transporters. Expert Rev Clin Pharmacol. 2008;1(5):627–47.CrossRefPubMed

20.

US Department of Health and Human Services. Guidance for Industry: drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf. Accessed 11 Dec 2018.

21.

Christensen H, Hermann M. Immunological response as a source to variability in drug metabolism and transport. Front Pharmacol. 2012;3:8.CrossRefPubMedPubMedCentral

22.

Huang SM, Temple R, Throckmorton DC, Lesko LJ. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther. 2007;81(2):298–304.CrossRefPubMed

23.

Tocilizumab [summary of product characteristics]. Welwyn Garden City: Roche. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125276s092lbl.pdf. Accessed 11 Dec 2018.

24.

Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735–40 (Erratum in Clin Pharmacol Ther. 2011 Sep;90(3):479).CrossRefPubMed

25.

Zhang X, Schmitt C, Grange S, Marino M. Disease-drug interaction studies of tocilizumab with cytochrome P450 substrates in vitro and in vivo. Clin Pharmacol Ther. 2009;85:S59.CrossRef

26.

Zhuang Y, de Vries DE, Xu Z, Marciniak SJ Jr, Chen D, Leon F, et al. Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. J Clin Pharmacol. 2015;55(12):1386–94.CrossRefPubMed

27.

de Andres F, LLerena A. Simultaneous determination of cytochrome P450 oxidation capacity in humans: a review on the phenotyping cocktail approach. Curr Pharm Biotechnol. 2016;17(13):1159–80.CrossRefPubMed

28.

Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, et al. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol. 2009;68(6):928–35.CrossRefPubMedPubMedCentral

29.

Gaedigk A, Ndjountche L, Divakaran K, Dianne Bradford L, Zineh I, Oberlander TF, et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther. 2007;81(2):242–51.CrossRefPubMed

30.

Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83(2):234–42.CrossRefPubMed

31.

Tremfya (guselkumab) [US prescribing information]. Horsham: Janssen Biotech, Inc. 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf. Accessed 11 Dec 2018.

32.

Center for Drug Evaluation and Research Multi-Discipline Review. Guselkumab: application number 761061Orig1s000. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761061Orig1s000MultidisciplineR.pdf. Accessed 11 Dec 2018.

33.

Ilumya (tildrakizumab) [US prescribing information]. Whitehouse Station: Merck & Co., Inc. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf. Accessed 11 Dec 2018.

34.

Center for Drug Evaluation and Research Multi-Discipline Review. Tildrakizumab: application number 761067Orig1s000. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761067Orig1s000MultdisciplineR.pdf.

35.

AbbVie. This study tests the effect of risankizumab on the metabolism in the liver of five additional drugs to study possible drug interactions in patients with psoriasis with or without psoriatic arthritis [ClinicalTrials.gov identifier NCT02772601]. US National Institutes of Health, ClinicalTrials.gov. 2016–2017. https://www.clinicaltrials.gov. Accessed 6 Dec 2018.

Title: Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis
Authors: Amit Khatri
Ling Cheng
Anne Camez
Stanislav Ignatenko
Yinuo Pang
Ahmed A. Othman
Publication date: 01-06-2019
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 6/2019
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-018-0730-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis

Abstract

Objective

Methods

Results

Conclusions

Clinical trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Clinical trial registration

Please log in to get access to this content

Other articles of this Issue 6/2019

Voriconazole: A Review of Population Pharmacokinetic Analyses

Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin

A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes

Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations

Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery